BERG has partnered with the MD Anderson Cancer Center to conduct trials of BPM31510 in solid tumors.
BERG, in conjunction with the Stanford University School of Medicine, is involved in a Phase 1 clinical trial for its drug candidate BPM 31510 in glioblastoma multiforme.
BERG has partnered with the Memorial Sloan Kettering Cancer Center to conduct clinical trials of BPM31543 in patients with chemotherapy-induced alopecia.
BIDMC has joined us in Project SurvivalSM, our unique collaborative effort focused on identifying biomarkers in pancreatic cancer to aid development of early detection diagnostics and individualized therapeutic approaches.
BERG and the Icahn School of Medicine at Mount Sinai have engaged in an R&D partnership to obtain novel insights into carcinogenesis, as well as the pathogenesis of neurological and endocrine disorders. The partnership will leverage bAIcis® in combination with Mount Sinai’s expertise in handling large datasets, advanced analytics and biological network modeling.
BERG is working with the University of Miami‘s Leonard M. Miller School of Medicine in the area of cardiovascular disease.
BERG and the Medical University of South Carolina have formed a strategic partnership focused on the management of lupus.
BERG and the Cleveland Clinic are engaged in a prospective clinical trial evaluating BERG’s prostate cancer biomarker panel.
BERG has partnered with Mount Sinai in Toronto to run prospective clinical trials of the multi-index prostate cancer diagnostic test.
BERG and the University Health Network are engaged in a retrospective clinical trial investigating BERG’s prostate cancer biomarker panel.